Immunosuppression: specific agents dosed before and after rituximab
| Drug . | Before rituximab . | After rituximab . |
|---|---|---|
| Prednisone | 29 | 26 |
| Tacrolimus | 28 | 27 |
| Mycophenolate | 23 | 20 |
| Sirolimus | 6 | 8 |
| Cyclosporine | 6 | 6 |
| Azathioprine | 4 | 3 |
| Basiliximab | 2 | 2 |
| IV immunoglobulin | 2 | 2 |
| Bortezomib | 1 | 2 |
| Antithymocyte globulin∗ | 14 | 2 |
| Drug . | Before rituximab . | After rituximab . |
|---|---|---|
| Prednisone | 29 | 26 |
| Tacrolimus | 28 | 27 |
| Mycophenolate | 23 | 20 |
| Sirolimus | 6 | 8 |
| Cyclosporine | 6 | 6 |
| Azathioprine | 4 | 3 |
| Basiliximab | 2 | 2 |
| IV immunoglobulin | 2 | 2 |
| Bortezomib | 1 | 2 |
| Antithymocyte globulin∗ | 14 | 2 |
Includes IS agents dosed 3 months before and after rituximab for the 32 patients who had a documented EBV viral load in the plasma compartment (international units per milliliter) within 3 months before and after rituximab.
IS, immunosuppression.
Antithymocyte globulin was given either for induction immunosuppression or for acute rejection in all cases.